source
- Summit and Akeso's ivonescimab beats Merck's Keytruda in Chinese NSCLC trialSummit Therapeutics and Akeso reported that their bispecific PD-1/VEGF antibody ivonescimab outperformed Merck's Keytruda in a Phase 3 HARMONi-2 trial conducted in China. The study enrolled first‑l…
- Scaling CAR-T: The hidden challenge of thousands of patient-specific manufacturing runsLegend Biotech and Johnson & Johnson’s Carvykti therapy illustrates the personal connection patients have with CAR-T, but also its unique operating model where each commercial dose is linked to an…